CoChat
Cited by 217

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Identification of Prognostic Factors in 61 Patients With Posttransplantation Lymphoproliferative Disorders

Leblond, Véronique, Dhedin, Nathalie, Bruneel, Marie-France Mamzer, Choquet, Sylvain, Hermine, Olivier, Porcher, Raphaël, Quoc, Stéphanie Nguyen, Davi, Frédéric, Charlotte, Frédéric, Dorent, Richard, Barrou, Benoit, Vernant, Jean-Paul, Raphael, Martine, Levy, Vincent · 2001 · Journal of Clinical Oncology

Abstract

PURPOSE: Prognostic studies of posttransplantation lymphoproliferative disorders (PTLDs) are hindered by the small number of cases at each transplant center. We analyzed prognostic factors and long-term outcome according to clinical manifestations, pathologic features, and treatment and investigated the prognostic value of the non-Hodgkin’s lymphoma International Prognostic Index (IPI) in 61 patients with PTLD. PATIENTS AND METHODS: We studied 61 patients in two institutions who developed PTLD and analyzed factors influencing the complete remission and survival rates. RESULTS: In univariate analysis, factors predictive of failure to achieve complete remission were performance status (PS) ≥ (P = .0001) and nondetection of Epstein-Barr virus (EBV) in the tumor (P = .01). Only a negative link with PS ≥ 2 was observed in multivariate analysis. In univariate analysis, factors predictive of lower survival were PS ≥ 2, the number of sites (one v > one), primary CNS localization, T-cell origin, monoclonality, nondetection of EBV, and treatment with chemotherapy. The IPI failed to identify a patient subgroup with better survival and was less predictive of the response rate than was a specific index using two risk factors (PS and number of involved sites), which defined three groups of patients: low-risk patients whose median survival time has not yet been reached, intermediate-risk patients with a median survival time of 34 months, and high-risk patients with a median survival time of 1 month. CONCLUSION: PS and the number of involved sites defined three risk groups in our population. The value of these prognostic factors needs to be confirmed in larger cohorts of patients treated in prospective multicenter studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2001.19.3.772

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 217

Metadata

Authors
Leblond, V., Dhedin, N., Bruneel, M.-F. M., Choquet, S., Hermine, O., Porcher, R., Quoc, S. N., Davi, F., Charlotte, F., Dorent, R., Barrou, B., Vernant, J.-P., Raphael, M., & Levy, V.
Venue
Journal of Clinical Oncology
Published
2001-02-01
Volume
19
Issue
3
Pages
772-778
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1933649159
Cited by
217
References
1
FWCI
3.53
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of Prognostic Factors in 61 Patients With Posttransplantation Lymphoproliferative Disorders. https://app.cochat.ai/papers/10.1200/jco.2001.19.3.772
The paper
Leblond, V., Dhedin, N., Bruneel, M.-F. M., Choquet, S., Hermine, O., Porcher, R., Quoc, S. N., Davi, F., Charlotte, F., Dorent, R., Barrou, B., Vernant, J.-P., Raphael, M., & Levy, V. (2001). Identification of Prognostic Factors in 61 Patients With Posttransplantation Lymphoproliferative Disorders. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2001.19.3.772

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.